Lymphoma patients may get a simpler shot option
NCT ID NCT05207670
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 37 times
Summary
This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for side effects like cytokine release syndrome, which can be treated with another drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alaska Oncology & Hematology, LLC
Anchorage, Alaska, 99508, United States
-
American Oncology Partners of Maryland, PA
Bethesda, Maryland, 20817-1915, United States
-
Astera Cancer Care East Brunswick
East Brunswick, New Jersey, 08816, United States
-
Cancer Specialists of North Florida - Jacksonville
Jacksonville, Florida, 32256, United States
-
City of Hope
Duarte, California, 91010, United States
-
Florida Cancer Specialists - EAST - SCRI - PPDS
West Palm Beach, Florida, 33401-3406, United States
-
Florida Cancer Specialists - NORTH - SCRI - PPDS
St. Petersburg, Florida, 33705-1449, United States
-
Infirmary Cancer Care
Mobile, Alabama, 36607-3513, United States
-
Kadlec Clinic Hematology and Oncology
Kennewick, Washington, 99336-7774, United States
-
Kaiser Foundation Hospitals
Portland, Oregon, 97227, United States
-
Mayo Clinic - PPDS
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054-4504, United States
-
Mayo Clinic Jacksonville - PPDS
Jacksonville, Florida, 32224-1865, United States
-
McGlinn Cancer Institute at Reading Hospital
West Reading, Pennsylvania, 19611, United States
-
Medical Oncology Hematology Consultants
Newark, Delaware, 19713-2055, United States
-
Mission Blood and Cancer - MercyOne Cancer Center
Des Moines, Iowa, 50314-3030, United States
-
MultiCare Deaconess Cancer and Blood Specialty Center
Spokane, Washington, 99218-8205, United States
-
NY Cancer & Blood Specialist
New York, New York, 10028-0506, United States
-
New York Cancer & Blood Specialists - Bronx
The Bronx, New York, 10469-5930, United States
-
New York Cancer & Blood Specialists - New Hyde Park
New Hyde Park, New York, 11042-1116, United States
-
New York Oncology Hematology, P.C.
Albany, New York, 12206, United States
-
North Shore Hematology Oncology Association PC
Shirley, New York, 11967, United States
-
Oncology Associates of Oregon, P.C.
Eugene, Oregon, 97401, United States
-
Oncology Hematology Care - SCRI
Zachary, Louisiana, 70791, United States
-
Oncology Hematology Care Inc - Cincinnati - USOR
Cincinnati, Ohio, 45236-2725, United States
-
Providence Cancer Institute
Portland, Oregon, 97213-2933, United States
-
Rocky Mountain Cancer Centers (Aurora) - USOR
Aurora, Colorado, 80012-5405, United States
-
SCRI Florida Cancer Specialists South
Fort Myers, Florida, 33916, United States
-
San Juan Oncology Associates
Farmington, New Mexico, 87401, United States
-
St. Vincent Frontier Cancer Center
Billings, Montana, 59101, United States
-
Tennessee Oncology - Nashville
Nashville, Tennessee, 37203, United States
-
Tennessee Oncology Chattanooga
Chattanooga, Tennessee, 37404-3230, United States
-
Texas Oncology (Amarillo) - USOR - 1826 Point West Pkwy
Amarillo, Texas, 79124-2167, United States
-
Texas Oncology (Tyler) - USOR
Tyler, Texas, 75702-8363, United States
-
Texas Oncology (Worth) - USOR
Dallas, Texas, 75246-2008, United States
-
Texas Oncology-Austin Midtown
Austin, Texas, 78705, United States
-
University of Kansas Medical Center
Westwood, Kansas, 66205, United States
-
VA Puget Sound Health Care System - NAVREF - PPDS
Seattle, Washington, 98108-1532, United States
-
Virginia Cancer Specialists - Gainsville
Gainesville, Virginia, 20155-3257, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mosunetuzumab
What this could lead to
If successful, this could provide a more convenient subcutaneous treatment option for certain B-cell lymphomas, potentially improving disease control.
What could go wrong
This is a mid-stage trial with no control group, so results are preliminary. Side effects like cytokine release syndrome (CRS) are possible, and the drug may not work for all lymphoma types studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.